The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | Update on ARI-0001 for patients with CD19+ R/R malignancies
ARI-0001 (varnimcabtagene autoleucel) is a novel second-generation autologous CD19 CAR-T cell that was evaluated in the Phase I CART19-BE-01 trial (NCT03144583). Clinical data showed ARI-0001 to be a safe and efficacious product, with persistence of CAR T-cells and response in patients with CD19+ relapsed/refractory (R/R) hematological malignancies. The CAR-T product is currently under review for approval by the Spanish Drug Agency (AEMPS) under the Hospital Exemption Rule. Manel Juan Otero, MD, PhD, Hospital Clínic de Barcelona, Barcelona, Spain, discusses the next steps for ARI-0001, including in combination with other approaches and finding new indications for the CAR-T product such as in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma. Additionally, Dr Juan Otero reveals that a new CAR T-cell targeting BCMA is being evaluated in multiple myeloma. This interview took place during the 3rd European CAR T-cell Meeting.
